コンテンツへスキップ
Merck

Modeling retinitis pigmentosa through patient-derived retinal organoids.

STAR protocols (2021-04-27)
Yan-Ping Li, Wen-Li Deng, Zi-Bing Jin
要旨

Human-induced pluripotent stem cells (hiPSCs) can be differentiated into well-structured retinal organoids. In this protocol, we successfully established 3D retinae from patient-derived hiPSCs and built the retinitis pigmentosa model in vitro. Moreover, mutation in the retinitis pigmentosa GTPase regulator (RPGR) gene was corrected by CRISPR-Cas9 gene editing, which rescued the structure and function of the 3D retinae. For complete details on the use and execution of this protocol, please refer to Deng et al. (2018).

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ジメチルスルホキシド, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Roche
DNase I, from bovine pancreas
Sigma-Aldrich
レチノイン酸, ≥98% (HPLC), powder
Sigma-Aldrich
MEM非必須アミノ酸溶液 (100X), without L-glutamine, liquid, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
1-チオグリセロール, liquid, BioReagent, suitable for cell culture, ≥97% (titration)
Sigma-Aldrich
抗オプシン抗体 赤/緑, Chemicon®, from rabbit
Sigma-Aldrich
G 418 二硫酸塩, suitable for plant cell culture, BioReagent
Sigma-Aldrich
モノクロナール抗オプシン マウス宿主抗体, clone RET-P1, ascites fluid
Sigma-Aldrich
Anti-Recoverin Antibody, serum, Chemicon®